Skip to main content
Welcome to
super saver spring
offer ends april 20
save over $140
save over 85%
per week for 24 weeks
Welcome to
super saver spring
per week
for 24 weeks
// //

Medical marijuana plants are pictured in the grow room on Jan. 21, 2016.

Dave Chan/The Globe and Mail

Patients who consumed tainted medical marijuana from government-regulated suppliers are questioning how safe the industry is in the wake of several high-profile recalls due to banned pesticides, which have exposed serious gaps in Health Canada's oversight.

After a string of recent recalls by Mettrum Ltd., OrganiGram Inc. and Aurora Cannabis Inc. because of the presence of myclobutanil – a banned pesticide that produces hydrogen cyanide when heated – a number of patients told The Globe and Mail they don't see how Health Canada can assure them the product can be trusted. Revelations that the government isn't testing regularly to prove all companies aren't using harmful chemicals have left consumers concerned for their health.

"I think this has probably given everybody a wakeup call," said Patty Wade, a Mettrum client in Trenton, Ont., who was prescribed medical cannabis for post-traumatic stress disorder. "When you are trusting a company to be healthy, you would have thought that the government would have ensured this."

Story continues below advertisement

Investigation: What's in your weed?

Related: No pesticide testing done for medical marijuana, Health Canada says

Read more: Medical marijuana recall expanded after banned pesticide found

Last week, Health Canada acknowledged to The Globe it had not been testing product from the 38 federally regulated medical-marijuana growers to ensure they weren't using banned chemicals.

Instead, the department said the companies knew pesticides such as myclobutanil were banned and the companies had been left to police themselves.

However, Thomas McConville, a former Mettrum employee, told The Globe he witnessed company employees spraying myclobutanil on plants to combat a mildew problem in 2014, even though they knew the chemical – a known carcinogen – was banned. To evade detection when Health Canada inspectors visited the facility, a Mettrum employee hid the pesticide behind the ceiling tiles in the company's offices, knowing the department wasn't testing the plants, Mr. McConville said.

Health Canada has since attached new conditions to the licences of Mettrum and OrganiGram, requiring their product to be tested for banned pesticides. And last week, the department announced random tests for the rest of the industry, which it hopes will ensure other companies aren't breaking the rules.

Story continues below advertisement

Without regular testing, though, there is no way to be certain which companies are producing clean product, patients say. Ms. Wade, a former nurse, said there is little certainty which companies are safe to buy her medicine from.

"What I'm hoping is that this has put such a spotlight on it, that the government is going to step up its processes and look into all of the licensed producers," Ms. Wade said. "I don't understand why they haven't been testing … So what are going to be the safeguards for us, the consumers?"

The licensed producers are already expected to test for mould and bacteria in their products before selling them. Health Canada said last week that, for now, it's not planning mandatory testing for banned pesticides. "We have a couple of cases right now. I wouldn't want to extrapolate that that's an issue that would be happening at all our LPs [licensed producers.]," a senior government official told The Globe.

Still, it's impossible for Health Canada to know how big the problem is. The Globe has talked to more than 20 patients affected by the recalls, and several of them say their confidence in the safety of the industry has been shaken.

"Presumably it's out of the product now – although who can even say that?" said Dawn Rae Downton, a patient in Halifax who was prescribed medical marijuana last March for severe back pain that prevented her from sleeping, and purchased her product from OrganiGram. "I see it as a consumer-protection issue, and I see it as an astonishing lack of oversight on the part of Health Canada."

In a submission to Health Canada, known as an Adverse Reaction Report, Ms. Downton told the department she suffered "severe, intractable nausea, vomiting and anorexia," which "continued relentlessly daily for nine months, resolving to a tolerable degree about five weeks after I stopped using the cannabis."

Story continues below advertisement

OrganiGram announced it was recalling her products in December, because of the presence of myclobutanil. Ms. Downton's symptoms are similar to several of the known effects of low-level hydrogen-cyanide poisoning on the body.

Health Canada has referred to the amounts of banned pesticide it detected as "trace amounts" that are "low risk." However, Warren Porter, a top U.S. toxicologist, questioned that response last week, saying, "There is no data I am aware of that would give those assurances. "Ultra-low doses can have all kinds of biological effects, especially over longer periods of exposure," said Dr. Porter, a specialist in molecular and environmental toxicology at the University of Wisconsin-Madison.

Ms. Downton is now worried about her health. "I inhaled hydrogen cyanide every day for eight months," she said.

Another patient told The Globe he chose to use medical marijuana for pain relief because he didn't want to use opioids. He selected a government-regulated supplier, Mettrum, because he wanted to ensure the product was safe and clean.

"I made a choice to go the medical-marijuana route, despite paperwork, numerous medical appointments and cost, because I wanted to feel safe about what I was putting in my body," said the man, who requested anonymity because he didn't want to disclose publicly he was using medical marijuana. "I felt this was safer."

The man said he is reluctant to purchase new product. "I don't trust the replacement product is safe," he said.

Story continues below advertisement

Only Mettrum and OrganiGram are now required to submit to regular testing for myclobutanil. The third recent recall, at Aurora Cannabis, came after that company purchased a bulk supply from OrganiGram, which it resold to its customers.

Since the recalls were announced in December, Mettrum was sold to Canopy Growth Corp. for $430-million. Mettrum chief executive Michael Haines has not responded to requests for comment. Mr. Haines is no longer with the company.

Canopy CEO Bruce Linton said the company is working to correct the Mettrum problems. Mr. Linton said he is in favour of routine testing to prove to customers the product is free of pesticides, which his company is adopting.

"The supply chain has to be completely trustworthy, and showing that you get that means that you will routinely and actively test and confirm this is on track, this is following the rules, there isn't what you wouldn't want in it," Mr. Linton said.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies